The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-21. Anything still debated is marked as such rather than presented as settled.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
In June the company announced it would acquire startup Emergence Therapeutics for an undisclosed sum and Sigilon Therapeutics for $300 million. The company's 2023 research and development focus has been reported to be on drugs in the obesity, diabetes, Alzheimer's and autoimmune areas. In March 2023, Eli Lilly announced a $35 cap on the price of monthly insulin to be put in place immediately in order to be in line with the Inflation Reduction Act. In July 2023, Lilly announced it would acquire Versanis for $1.93 billion. In October 2023, Eli Lilly acquired Point Biopharma for $1.4 billion. In November 2023, the FDA approved tirzepatide for the treatment of obesity under the brand name Zepbound. In 2024, the FDA and the UK approved Donanemab, sold under the brand name Kisunla, a monoclonal antibody used for the treatment of Alzheimer's disease. In January 2026, Eli Lilly agreed to buy Ventyx Biosciences for $1.2 billion. The transaction was expected to close in 1H 2026. In March 2026, Eli Lilly announced a drug discovery deal with InSilico for an estimated value of $2.75 billion. In July 2026, Eli Lilly entered into an agreement to acquire AtaiBeckley in 2026.
These are sympatholytic drugs that block the effects of adrenergic alpha receptors while having little or no effect on beta receptors. Drugs belonging to this group can have very different effects, however, depending on whether they primarily block alpha-1 receptors, alpha-2 receptors, or both. Alpha-2 receptors, as described elsewhere in this article, are frequently located on norepinephrine-releasing neurons themselves and have inhibitory effects on them; consequently, blockage of alpha-2 receptors usually results in an increase in norepinephrine release. Alpha-1 receptors are usually located on target cells and have excitatory effects on them; consequently, blockage of alpha-1 receptors usually results in blocking some of the effects of norepinephrine. Drugs such as phentolamine that act on both types of receptors can produce a complex combination of both effects. In most cases when the term "alpha blocker" is used without qualification, it refers to a selective alpha-1 antagonist. Selective alpha-1 blockers have a variety of uses. Since one of their effects is to inhibit the contraction of the smooth muscle in the prostate, they are often used to treat symptoms of benign prostatic hyperplasia. Alpha-blockers also likely help people pass their kidney stones. Their effects on the central nervous system make them useful for treating generalized anxiety disorder, panic disorder, and posttraumatic stress disorder. They may, however, have significant side effects, including a drop in blood pressure.
US legislators expressed similar concerns, and bipartisan investigations were launched by the Senate and the House Armed Services Committees. On 17 December, the Senate passed the National Defense Authorization Act for Fiscal Year 2026 with a bipartisan amendment that, if passed by the House, would require Hegseth to provide unedited footage of the strikes and their authorizing orders to both committees or lose part of his travel budget.
== Self-replication == "Molecular assemblers" have been confused with self-replicating machines. To produce a practical quantity of a desired product, the nanoscale size of a typical science fiction universal molecular assembler requires an extremely large number of such devices. However, a single such theoretical molecular assembler might be programmed to self-replicate, constructing many copies of itself. This would allow an exponential rate of production. Then, after sufficient quantities of the molecular assemblers were available, they would then be re-programmed for production of the desired product. However, if self-replication of molecular assemblers were not restrained then it might lead to competition with naturally occurring organisms. This has been called ecophagy or the grey goo problem. One method of building molecular assemblers is to mimic evolutionary processes employed by biological systems. Biological evolution proceeds by random variation combined with culling of the less-successful variants and reproduction of the more-successful variants. Production of complex molecular assemblers might be evolved from simpler systems since "A complex system that works is invariably found to have evolved from a simple system that worked. . . . A complex system designed from scratch never works and can not be patched up to make it work. You have to start over, beginning with a system that works." However, most published safety guidelines include "recommendations against developing ... replicator designs which permit surviving mutation or undergoing evolution".
Sources: en.wikipedia.org
Furthermore, the different compounds are divided into multiple categories (classical, novel, second generation, third generation) depending on the chemical structures. An example of a compound is benzoate, which is a classical inhibitor. The carboxylic group of benzoate interacts with Arg238, and the aromatic interacts with Tyr224 on the active zone of the oxidase.
== Superintendent/CEO == In 2013, a governance reorganization led by then-County Executive Rushern Baker renamed the superintendent position to chief executive officer of PGCPS. Dubbed a 'takeover' of the county's school system, this shift increased the operational control for the CEO while limiting the school board's powers. Dr. Kevin Maxwell was the inaugural CEO of Prince George's County Public Schools, serving until 2018. He was succeeded by Dr. Monica Goldson, who remained in the position through the 2022–23 school year. After a rigorous 6-month nationwide search, the district shortlisted three candidates. Following an interview with County Executive Angela Alsobrooks, Millard House II, former Superintendent of the Houston Independent School District, was chosen to succeed Dr. Goldson. With House's appointment as Superintendent in June 2023, the district ceased referring to its head as CEO. Dr. Shawn Joseph was appointed interim superintendent for the 2025–2026 school year. On June 1, 2026, the appointment of Dr. Joseph to the Superintendent role was made permanent.
=== Variations === Type 1 juncturae is mostly seen between the index and the middle fingers (second inter metacarpal space). Type 2 juncturae is observed mainly between the middle and the ring fingers (third inter-metacarpal space). Type 3 juncturae tendinum is mostly found between the ring and the little finger (fourth inter-metacarpal space). Normally, the extensor indicis proprius do not receive any juncture tendinum, but it is rarely seen and the mobility of the index finger is compromised. The absence of the tendon of the extensor digitorum communis to the little finger is associated with the thicker type 3r juncturae tendinum in the fourth intermetacarpal space. Hirai et al. reported type 1 junturae tendinum between the extensor digiti minimi and the extensor digitorum communis to the ring finger in 6% of the specimens.
== History and taxonomy == Penicillium digitatum is a species within the Ascomycota division of Fungi. The genus name Penicillium comes from the latin word "penicillus", which means brush, referring to the branching appearance of the asexual reproductive structures found within this genus. As a species, P. digitatum was first noted as Aspergillus digitatus by Christiaan Hendrik Persoon in 1794, who later adopted the name Monilia digitata in Synopsis methodica fungorum (1801). The synonym M. digitata can also be found in the writings of Elias Magnus Fries in Systema Mycologicum. However, the current binomial name comes from the writings of Pier Andrea Saccardo, particularly Fungi italici autographie delineati et colorati (1881).
Tel Yavne was first excavated in 2005 in a dig headed by Dan Bahat, who unearthed the gate room of the Crusader castle of Ibelin, as well as a vault destroyed with gunpowder by the Mamluks and deeply embedded Crusader walls east of it, all at or around the top of the tell. In December 2019, a large number of pottery kilns and 1,200-year-old gold coins which may have been a local potter's "piggy bank" were unearthed in a juglet by the Israel Antiquities Authority. According to archaeologist Robert Kool, the coins date back to the early Abbasid period, about 9th century CE. One of the seven coins was minted by Caliph Harun al-Rashid (786–809 CE). "These are gold dinars issued by the Aghlabid dynasty that ruled in North Africa. Without a doubt this is a wonderful Hanukkah present for us," said Kool. In August 2020, Israeli archaeologists discovered 425 complete gold coins, most dating to the Abbasid period around 1,100 years ago. In April 2021, archaeologists announced the discovery of a 1,600-year-old multicolored mosaic dated back to the Byzantine period in an industrial area. According to IAA archaeologist Elie Haddad, it was the first time that excavators revealed a colored mosaic floor in Yavne. The ancient harbour of Yavne, Yavne-Yam (in Arabic Minet Rubin) was identified on the coast. Excavations have revealed fortification going back to the Bronze Age Hyksos. It was in use from the Middle Bronze Age until the 12th century CE, when it was abandoned.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.